China adjustment of crown disease epidemic prevention and control measures, no longer check nucleic acid detection negative proof, nucleic acid test arrangement adjustment adjustmentIn order to "non -nucleic acid" and "willing to check the inspection", a number of listed companies with nucleic acid testing business claimed that they would put more energy into the conventional business before the epidemic.Not Comprehensive Surging News and 21st Century Economic Herald, China further optimizes epidemic prevention policies. Except for special groups, most people travel and shopping are no longer subject to nucleic acid restrictions.NotFarewell to the normalization of nucleic acid detection, a number of listed companies involving nucleic acid testing have stated that they will return their business to the conventional business before the epidemic.
Now not only faces the problem of price decline, but also faces business atrophy risks.Lan Wei Medical stated that "the business will not have a great impact, and the company's other detection business in the epidemic is done well, and it will strengthen the business of the nucleic acid detection."Angine said in an interview, "This year's business will not be affected. This impact will be next year, and it depends on the adjustment of specific policies."SPAN> Lanwei Medical Company has predicted in the semi -annual report that "with the national epidemic prevention and control stage adjustment and the launch of new crown therapy drugs, the epidemic will be effectively controlled.Routine inspection but will be accompanied by price reduction, so the company's new crown test income and gross profit may decrease, and there is a risk of declining operating performance. "
Kaipu creature said on November 28th on the investor interactive platform on November 28.As of now, the company (including Hong Kong) has completed a total of about 800 million people in 2022.The company will have more energy to invest in conventional business. Whether (nucleic acid detection business) will have an impact depends on the adjustment of policies in various places.Not Huada Gene states that nucleic acid testing is not the direction of the company's development, and the business will return to the state before the epidemic, such as expanding overseas business.At present, antigen self -testing, nucleic acid detection, nucleic acid fast test, variation detection, virus sequencing and neutralized antibody detection, etc., can meet different use needs and application scenarios.Not According to 15 companies selected by Surging News, the total revenue of these companies in the third quarter of this year was 87.7 billion yuan (RMB, the same below, about 17 billion yuan), with an average ofThe revenue increased by 60 %, but the accounts receivable reached 44 billion yuan, and the accounts receivable increased by 70 %.Not According to analysis, the third quarter report of Lanwei Medical shows that the operating cash flow is 244 million yuan, an increase or decrease of -366.1%at the same time, showing that the decrease in the net cash flowEssenceNot The net operating cash flow of Dian Gene was 287 million yuan, an increase of 32.41%year -on -year, but it was 84.18%of the increase in accounts receivable, which means that the burden on the enterprise is increasing.Not However, in the interview, the above -mentioned enterprises said that there was no problem with the receivables.Not Dian Gene and Kaipu said that the arrears are mainly government, hospitals, and third -party testing agencies, all of which are institutions with good reputation and lower risks.
